UNSPSC 51334505: Butaclamol hydrochloride

This classification denotes the hydrochloride form of a dopamine antagonist with the molecular formula C25H31NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A7A2802VNL, chemically known as 1h-benzo(6,7)-cyclohepta(1,2,3-de)pyrido(2,1-a)isoquinolin-3-ol, 3-(1,1-dimethylethyl)-2,3,4,4a,8,9,13b,14-octahydro-, (3alpha,4aalpha,13bbeta)-(+-)- but more generally known as butaclamol, which bears US NIH Compound Identifier 37459. Butaclamol most often comes in base and hydrochloride forms.

UNSPSC 51334505 Butaclamol hydrochloride is a Commodity code that nominally covers a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code shows little direct relevance to butaclamol itself. Instead, issuing bodies are procuring broader pharmaceutical and drug-management products and services—including naloxone (an opioid antagonist used in overdose response), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through state health and human services channels. The issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, which includes Oregon participants). The code appears to capture pharmaceutical procurement more broadly rather than butaclamol specifically, suggesting the tagging may reflect a catch-all pharmaceutical commodity classification or a legacy categorization that does not align tightly with the actual products being solicited.

Activity is concentrated in Florida, Texas, and the upper Midwest (Minnesota, Oregon). Seminole County, Florida released an Invitation for Bid (IFB 60459723LAS) on June 30, 2026, with a due date of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the contract includes a two-year initial term with a one-year renewal option and is potentially FEMA-funded. The Texas Health and Human Services Commission posted a Request for Information (RFI HHS0017013) on April 3, 2026 to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with responses due the same day. The Minnesota Multistate Cooperative Purchasing Alliance, administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) posted January 20, 2026, with a proposal deadline of March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with an effective date of July 1, 2026. These three solicitations represent the primary recent activity under the code.